Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.55 |
| ▸ | CNOT7 | Q9UIV1 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PARN | O95453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL6829135 | 0.82 | ADORA2A (0.46) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Pentaerythritol Tetranitrate SCHEMBL6829132 | 0.80 | ADORA2B (0.44) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL447390 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9574927 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5510062 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9949244 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL10996 | 0.78 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL9682658 | 0.76 | ADORA2B (0.96) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL7296127 | 0.76 | ADORA2B (0.62) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6555067 | 0.76 | ADORA2B (0.57) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| CN-114814016-A | Method for rapidly detecting whether rhizoma atractylodis sinensis is doped in rhizoma atractylodis medicinal material | 湖北省药品监督检验研究院 | 2022-07-29 | — | — | CN | claimed |
| US-11324705-B2 | Transdermal drug delivery system | AVRO LIFE SCIENCES, INC. (CA) | 2022-05-10 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| CN-113144061-A | Cough-relieving traditional Chinese medicine external preparation and preparation method thereof | 尼腾(广州)生物科技有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| EP-0644887-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID. | SMITHKLINE BEECHAM PLC (GB) | 1995-03-29 | — | — | EP | claimed |
| WO-1993025557-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1993-12-23 | — | — | WO | claimed |
| EP-0371844-B1 | USE OF ALPHA-TOCOPHEROL, BENZYL, XANTHINOL OR HEXYL NICOTINATE OR ALPHA TOCOPHEROL ACETATE IN A COSMETIC OR PHARMACEUTICAL SLIMMING COMPOSITION | L'OREAL (FR) | 1992-07-29 | — | — | EP | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| EP-0151987-B1 | MEANS FOR THE TREATMENT OF DISEASES OF THE VEINS AND THE ANAL REGION | Ismail, Roshdy, Dr. (DE) | 1991-05-29 | — | — | EP | claimed |
| EP-0371844-A2 | Use of alpha-tocopherol, benzyl, xanthinol or hexyl nicotinate or alpha tocopherol acetate in a cosmetic or pharmaceutical slimming composition | L'OREAL (FR) | 1990-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ADORA2B 500/4885ADORA2A 634/4885PDE4A 325/4885 |
| US-11324705-B2 | Transdermal drug delivery system | CUTA, AQP1, SLC26A4 | ADORA2B 3147/4885ADORA2A 2115/4885PDE4A 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.